Lanza Delivered Keynote Address at Brown University's 5th Annual Biotech Expo
ALAMEDA, Calif.-- (BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB:ACTC - News), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, has announced that Dr. Robert Lanza, the Company's Vice President of Research and Scientific Development, has been recognized for his groundbreaking research and contributions in stem cell science and biology with a special award from Brown University's Biotechnology Interest Group.
The Brown University biotech group made the award for "Outstanding Contribution in Contemporary Biology” to Dr. Lanza at the organization's 5th Annual Biotech Expo, held February 1, 2006, at Brown's Providence, R.I., campus. Dr. Lanza also delivered a keynote address at the conference.
Dr. Lanza is a noted pioneer in the field of stem cell science, with more than 25 years experience in the application of stem cells in regenerative medicine. He has published several hundred papers, patents and innovations relating to stem cell science, among them ACTC's Single Cell Blastomere method to derive human embryonic stem cells without harming the donor embryos' potential for life.
"This award helps bring additional notice to the stem cell industry at a point when the field is entering an exciting period of clinical development,” said Dr. Lanza. "At ACTC and at institutions around the world, we are focused on the development of powerful new products that have the potential to revolutionize treatment for a growing number of serious diseases and injuries.”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
For more information, please visit: "www.advancedcell.com":http://www.advancedcell.com.
For investor-specific information and resources, visit "http://www.trilogy-capital.com/tcp/advancedcell":http://www.trilogy-capital.com/tcp/advancedcell.
To read or download Advanced Cell's Investor Fact Sheet, please visit "http://www.trilogy-capital.com/tcp/advancedcell/factsheet.html":http://www.trilogy-capital.com/tcp/advancedcell/factsheet.html.
To view recent stock quotes and news, visit "http://www.trilogy-capital.com/tcp/advancedcell/quote.html":http://www.trilogy-capital.com/tcp/advancedcell/quote.html.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
The Investor Relations Group
Investors: "James Carbonara":mailto:firstname.lastname@example.org, 212-825-3210
Media: "Bill Douglass":mailto:email@example.com, 212-825-3210
Trilogy Capital Partners
"Paul Karon":mailto:firstname.lastname@example.org, 800-592-6067